Zoom Scheduler, now generally available, allows users to align calendars with clients and contacts quickly and easily

Zoom extends free signup period for Zoom Scheduler to July 20

SAN JOSE, Calif., June 21, 2023 (GLOBE NEWSWIRE) — Today, Zoom announced general availability for its new Zoom Scheduler tool and the extension of the free signup period. Zoom Scheduler makes finding the perfect meeting time easier by sharing availability for others to conveniently book appointments.

“We heard again and again from our customers that they were looking for a convenient way to book appointments without leaving the Zoom platform,” said Joseph Chong, Head of Product, Solutions, and Industry Marketing, Zoom. “With Zoom Scheduler, they can. Based on positive feedback, we will be offering Zoom Scheduler for free for anyone to try for one more month.”

Zoom is known for simplifying collaboration tools, and its latest product has taken on everyone’s least favorite meeting task: aligning calendars. Sharing availability windows back and forth manually takes up valuable time and adds more friction to a workday. Meeting with potential customers or clients often compounds this problem, as external participants lack visibility into one another’s calendars. Zoom Scheduler allows hosts to generate windows of availability that others can use to book appointments. With Zoom Scheduler, users will be able to grow their businesses faster and get more done so they can spend more time on what matters: preparing for the meeting or taking a break.

Get together with Zoom Scheduler

Now generally available, Zoom Scheduler places a meeting on the host’s calendar with a Zoom Meetings link already included, saving both participants time. Hosts can use their preferred calendar: Zoom Scheduler works seamlessly with Zoom Meetings and Zoom Mail and Calendar and integrates with both Google Calendar and Microsoft 365.

Features of Zoom Scheduler include:

  • Ability to schedule one-on-one meetings or one-to-many group meetings and specify how many people can attend any available slot.
  • Choose recurring availability or custom availability for one-off meetings.
  • Generate slots of availability when any or all team members are available.
  • Automate and customize email notifications.
  • Collect preferred information during the attendee booking process.

Beta customers love how Zoom Scheduler saves time and consolidates meeting scheduling where it makes the most sense: in the middle of the communication platform they know and love.

“Zoom Scheduler offers an easy, no-effort integration with the rest of the Zoom platform,” said Gabe Moronta, Visla. “It has all the features, settings, and capability I need.”

Zoom Scheduler integrates with Zoom Calendar, which has become a resource for meetings both before and after. Zoom Calendar offers a sidebar view alongside the Zoom desktop client, so attendees can maximize their time by seeing if others have joined the meeting yet. After the meeting, shared files live in the Calendar invite for future reference.

Free and paid Zoom users can try out Zoom Scheduler for free anytime before July 19, 2023. On July 20, 2023, Scheduler will be available as an add-on for purchase for $5.99/month per user on Zoom’s website (add to any existing legacy Zoom plan or Zoom One plan), and will be included in the Zoom One Business Plus and Enterprise Plus plans.

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Zoom Public Relations
Lacretia Taylor
press@zoom.us

GlobeNewswire Distribution ID 8862086

Curia Expands Cell Line Development Offering with CHOZN Platform

Curia signs license agreement with MilliporeSigma to support production of proteins and antibodies

ALBANY, N.Y., June 20, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has signed a licensing agreement with MilliporeSigma, the North American Life Sciences Business of Merck KGaA, Darmstadt, Germany, that enables Curia and its clients to use the CHOZN® GS-/- cell line for production of therapeutic proteins and antibodies. Following the agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers.

CHOZN® platform is a Chinese Hamster Ovary (CHO) mammalian cell expression system that allows for faster, simpler selection and scale-up of high-producing clones for production of biologics and therapeutic recombinant proteins. It includes high-performing CHO cell lines, paired media and feeds, optimized expression vectors and robust protocols. The glutamine synthetase GS knockout (GS-/-) cell line of the CHOZN platform is specially designed to help streamline selection, identification and scale-up of high-producing clones ideal for GMP manufacturing of recombinant protein drugs.

“We continue to strengthen our biologics development offerings from discovery through clinical manufacturing,” said Christopher Conway, President R&D, Curia. “The CHOZN GS-/- cell line platform adds a widely accepted and commercially viable cell line to our capabilities. Our integrated offering accelerates therapeutic protein and antibody production and offers seamless tech transfer for optimal flexibility.”

Curia’s protein and antibody development experts offer a track record of accelerating progress, with a timeline in as little as 12 months from cell line development to phase I drug substance, depending on the manufacturability of the candidates.

The addition of the CHOZN platform strengthens Curia’s offerings as a complement to its existing proprietary CHO cell line, providing customers with a highly versatile and broadly applicable solution.

About Curia
Curia is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s nearly 4,000 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

GlobeNewswire Distribution ID 8859845

Curia étend son offre de développement de lignées cellulaires avec la plateforme CHOZN

Curia signe un accord de licence avec MilliporeSigma pour soutenir la production de protéines et d’anticorps

ALBANY, État de New York, 20 juin 2023 (GLOBE NEWSWIRE) — Curia, une organisation de recherche, développement et fabrication en sous-traitance de premier plan, a annoncé aujourd’hui avoir signé un accord d’octroi de licence avec MilliporeSigma, l’entreprise nord-américaine de sciences de la vie de Merck KGaA, basée à Darmstadt, en Allemagne, qui permet à Curia et à ses clients d’utiliser la lignée cellulaire CHOZN® GS-/- pour la production d’anticorps et de protéines thérapeutiques. Suite à l’accord, la lignée cellulaire CHOZN GS-/- a été intégrée dans le workflow de développement de lignées cellulaires de Curia et est immédiatement disponible pour les clients de Curia.

La plateforme CHOZN® est un système d’expression de cellule mammalienne d’ovaire de hamster chinois (Chinese Hamster Ovary, CHO) qui permet une sélection et un accroissement plus rapides et plus simples de clones très prolifiques pour la production d’agents biologiques et de protéines recombinantes thérapeutiques. Cela inclut des lignées cellulaires CHO ultra-performantes, des milieux et cultures appairés, des vecteurs d’expression optimisés et des protocoles robustes. La lignée cellulaire glutamine synthéase GS knockout (GS-/-) de la plateforme CHOZN est spécifiquement conçue pour aider à rationaliser la sélection, l’identification et l’accroissement de clones prolifiques idéaux pour la fabrication de médicaments à base de protéines recombinantes respectant les BPF.

« Nous continuons de renforcer nos offres de développement de produits biologiques de la découverte à la fabrication clinique », a déclaré Christopher Conway, président de la R&D chez Curia. « La plateforme de lignées cellulaires CHOZN GS-/- ajoute une lignée cellulaire largement acceptée et commercialement viable à nos capacités. Notre offre intégrée accélère la production d’anticorps et de protéines thérapeutiques et propose un transfert technologique harmonieux pour une flexibilité optimale. »

Les experts du développement d’anticorps et de protéines de Curia ont un historique éprouvé pour ce qui est d’accélérer le progrès, avec un calendrier de seulement 12 mois entre le développement de lignées cellulaires et la substance médicamenteuse de phase I, selon la facilité de fabrication des candidats.

L’ajout de la plateforme CHOZN renforce les offres de Curia en tant que complément de sa lignée cellulaire CHO exclusive actuelle, offrant aux consommateurs une solution ultra-polyvalente et largement applicable.

À propos de Curia
Curia est une organisation de recherche, développement et fabrication en sous-traitance de premier plan qui fournit des produits et services allant de la R&D aux clients pharmaceutiques et biopharmaceutiques en passant par la fabrication commerciale. Basés sur 29 sites à travers les États-Unis, l’Europe et l’Asie, les près de 4 000 employés de Curia aident les clients de l’entreprise à passer de la curiosité à la guérison. Pour en savoir plus, rendez-vous sur CuriaGlobal.com.

Contact chez Curia :
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

GlobeNewswire Distribution ID 8860042

Floship Becomes Second Recipient of Investment from FedEx Innovation Lab

The investment marks a significant milestone and signals a new era in the development of the future of global circular e-commerce fulfillment services.

HONG KONG, June 19, 2023 (GLOBE NEWSWIRE) — Leading global circular supply chain solutions provider, Floship, has announced today that it has received an investment from FedEx Innovation Lab (FIL). This investment by FIL will strengthen Floship’s capabilities to extend its service offering to new markets. Floship is poised to collaborate with FedEx to build an end-to-end digitalized fulfillment and return solution that will create smart logistics for all.

This partnership will give FedEx e-commerce customers access to Floship’s global network of warehouses and powerful logistics platform’s capabilities to streamline their e-commerce fulfillment operations. At the same time, Floship’s customers will be able to leverage FedEx global networks as well as a full range of FedEx extensive transportation options to optimize their operations.

FedEx Innovation Lab makes early-stage investments in rising start-ups to bring additional value in terms of capabilities and speed to market to start-up firms through the FedEx global network, resources, and customer base.

Josh Tsui, CEO of Floship, commented on the investment, “It’s an honor for Floship to be collaborating with FedEx. This is a significant milestone in Floship’s journey to becoming the leading circular supply chain and fulfillment solution provider worldwide. It is a testament to our e-commerce clients about the future strategic direction of Floship and enhancements to our service offering,” said Tsui.

About Floship

Floship’s global circular supply chain ecosystem solutions cover all aspects of the global supply chain, ensuring minimal operation effort for e-commerce businesses, and allowing business owners to concentrate on driving growth with investment flexibility while gaining peace of mind.

Learn more at www.floship.com or follow us on LinkedIn.

For more information about Floship, please contact:

James Linacre, PR & Communications Lead

Phone: (+852) 5333 9420

Email: pr@floship.com

GlobeNewswire Distribution ID 8860144

Floship Torna-se Segunda Beneficiária de Investimento da FedEx Innovation Lab

O investimento é um marco significativo e sinaliza uma nova era no desenvolvimento do futuro dos serviços de atendimento de e-commerce circular global.

HONG KONG, June 19, 2023 (GLOBE NEWSWIRE) — A Floship, principal fornecedora global de soluções de cadeia de suprimentos circulares, anunciou hoje que recebeu um investimento da FedEx Innovation Lab (FIL). Este investimento da FIL fortalecerá a capacidade da Floship de ampliar sua oferta de serviços em novos mercados. A Floship está pronta para colaborar com a FedEx para o desenvolvimento de uma solução completa de atendimento e devolução digitalizada que crie uma logística inteligente para todos.

Essa parceria proporcionará aos clientes de e-commerce da FedEx acesso à rede global de depósitos da Floship e aos recursos da potente plataforma de logística para agilizar suas operações de atendimento de e-commerce. Além disso, os clientes da Floship poderão aproveitar as redes globais da FedEx, bem como uma ampla gama de opções de transporte da FedEx para otimizar suas operações.

A FedEx Innovation Lab faz investimentos iniciais em startups em ascensão para agregar valor adicional em termos de capacidade e velocidade de lançamento no mercado para empresas iniciantes por meio da rede global, recursos e base de clientes da FedEx.

Josh Tsui, CEO da Floship, comentou sobre o investimento: “É uma honra para a Floship colaborar com a FedEx. Este é um marco significativo na jornada da Floship para se tornar o principal fornecedor de soluções de cadeia de suprimentos e atendimento circular em todo o mundo. É uma indicação para os nossos clientes de e-commerce da futura direção estratégica da Floship e das melhorias da nossa oferta de serviços”, disse Tsui.

Sobre a Floship

As soluções de ecossistema de cadeia de suprimentos circular global da Floship abrangem todos os aspectos da cadeia de suprimentos global, garantindo um esforço operacional mínimo para as empresas de comércio eletrônico e permitindo que os proprietários de empresas se concentrem em impulsionar o crescimento com a flexibilidade do investimento e, ao mesmo tempo, ter tranquilidade.

Saiba mais em www.floship.com ou siga-nos no LinkedIn,

Para mais informações sobre a Floship, contate:

James Linacre, Líder de Relações Públicas e Comunicações

Telefone: (+852) 5333 9420

Email: pr@floship.com

GlobeNewswire Distribution ID 8860146